ClinicalTrials.gg

Program

IPG11406

A development code. Also written as “IPG11406 tablet”.

Its studies are mostly in Lupus Nephritis · Colitis, Ulcerative · Inflammatory Bowel Diseases, led by Nanjing Immunophage Biotech.

Furthest: phase 2, since Nov 26, 20244 company-led studies, 2 open or runningNext primary completion: Nov 20, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing Immunophage Biotech42 open or runningphase 2since Nov 26, 2024Dec 25, 2023Nov 20, 2028phase 2 · NCT07937501

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 25, 2023First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT06255834 · 66 enrolled · China
  2. Nov 26, 2024Phase 2 study in Lupus NephritisNCT06717815 · 24 enrolled · China
  3. Apr 10, 2026Phase 2 study in Moderately to Severely Active Ulcerative Colitis (UC)NCT07535489 · 144 planned · China
  4. Nov 8, 2026Phase 2 study in Lupus NephritisNCT07937501 · 192 planned · China

Ahead

  1. Nov 20, 2028Primary completion: phase 2 study in Lupus NephritisNCT07937501
  2. Dec 1, 2028Primary completion: phase 2 study in Moderately to Severely Active Ulcerative Colitis (UC)NCT07535489

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07937501Lupus Nephritis · China2Not yet recruitingNov 20, 2028192
NCT07535489Moderately to Severely Active Ulcerative Colitis (UC) · China2RecruitingDec 1, 2028144
NCT06717815Lupus Nephritis · China2CompletedJun 8, 202624
NCT06255834Inflammatory Bowel Diseases · China1CompletedDec 30, 202466

How it is read

Names in the registry

  • “IPG11406”, 3 entries
  • “IPG11406 tablet”, 1 entry

Codes read as this program: IPG11406.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.